5Christians U.Transport proteins and intestinal metabolism; P-glycoproteinand cytochrome P4503A.. Therapeutic Drug Monitoring . 2009
6Hirunpanich V,KatagiJ,Sethabouppha B,et al.Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates:in vitro and in vivo evidence using cyclosporin in rats. Drug Metab.Dispos . 2008
7Midtvedt K.Therapeutic drug monitoring of cyclosporine. Transplant,Proc . 2009
8Hirunpanich V,Murakoso K,Sato H.Inhibitory effect of docosahexaenoic acid (DHA-EE) on the intestinal metabolism of midazolam;in vitro and in vivo studies in rats. Int.].Pharm . 2008
9Hirunpanich V,Sato H.Docosahexaenoic acid (DHA-EE) inhibits saquinavirmetabolism in vitro and enhances its bioavailability in rats. Pharm- Pharmacol . 2010
10Hiroshi ARAYA,Mikio TOMITA,Masahiro HAYASHI.The novel formulation design of serf-emulsifying drug delivery systems(SEDDS)type O/W microemul- sionⅢ:The permeation mechanism of a poorly water soluble drug entrapped O/W mieroemulsion in rat isolated intestinal membrane by the uasing chamber methad. Drug Metab Pharmacokinet . 2006
